Better Buy: Johnson & Johnson vs. Merck
This big pharma claims one of the hottest cancer drugs around. But it also faces challenges for some of its biggest-selling drugs. Which big pharma is it?
Actually, it's two: Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK).
These companies are similar in several ways. However, Johnson & Johnson stock is up big in 2017, while Merck stock has lost ground this year. Will J&J continue to be the better pick, or will Merck roar back? Here's how these pharma stocks compare.
Source: Fool.com
Johnson & Johnson Stock
€221.05
-0.230%
The stock is an absolute favorite of our community with 57 Buy predictions and no Sell predictions.
With a target price of 228 € there is a slightly positive potential of 3.14% for Johnson & Johnson compared to the current price of 221.05 €.
